280 related articles for article (PubMed ID: 32356859)
21. Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Heeb SR; Schaller M; Kremer Hovinga JA
J Immunol; 2022 Jun; 208(11):2497-2507. PubMed ID: 35589126
[TBL] [Abstract][Full Text] [Related]
22. Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Lin C; Memon R; Sui J; Zheng XL
Cerebrovasc Dis Extra; 2021; 11(1):29-36. PubMed ID: 33601375
[TBL] [Abstract][Full Text] [Related]
23. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
Chen M; Shortt J
Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
[TBL] [Abstract][Full Text] [Related]
24. ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications.
Dainese C; Valeri F; Pizzo E; Valpreda A; Sivera P; Montaruli B; Porreca A; Massaia M; Bruno B; Borchiellini A
Clin Appl Thromb Hemost; 2022; 28():10760296221125785. PubMed ID: 36124377
[TBL] [Abstract][Full Text] [Related]
25. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
26. Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.
Sakai K; Miyadera H; Kubo M; Nakajima F; Matsumoto M
J Thromb Haemost; 2023 Mar; 21(3):616-628. PubMed ID: 36696200
[TBL] [Abstract][Full Text] [Related]
27. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
[TBL] [Abstract][Full Text] [Related]
29. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
Sui J; Zheng L; Zheng XL
Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210
[TBL] [Abstract][Full Text] [Related]
30. An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Joly BS; Peetermans M; Verhamme P; Voorberg J; Greinacher A; Deckmyn H; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
J Thromb Haemost; 2018 Feb; 16(2):378-388. PubMed ID: 29222940
[TBL] [Abstract][Full Text] [Related]
31. Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management.
Roose E; Veyradier A; Vanhoorelbeke K
Curr Opin Hematol; 2020 Sep; 27(5):320-326. PubMed ID: 32740038
[TBL] [Abstract][Full Text] [Related]
32. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
Cataland SR; Jin M; Lin S; Kraut EH; George JN; Wu HM
Am J Hematol; 2008 Dec; 83(12):911-5. PubMed ID: 18821711
[TBL] [Abstract][Full Text] [Related]
33. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
34. A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura.
Falter T; Rossmann H; de Waele L; Dekimpe C; von Auer C; Müller-Calleja N; Häuser F; Degreif A; Marandiuc D; Messmer X; Sprinzl M; Lackner KJ; Jurk K; Vanhoorelbeke K; Lämmle B
Blood Adv; 2023 Sep; 7(17):5091-5102. PubMed ID: 37399489
[TBL] [Abstract][Full Text] [Related]
35. Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura.
Comparon C; Galicier L; Rebibou JM; Coppo P; Benhamou Y
Eur J Haematol; 2023 Feb; 110(2):157-160. PubMed ID: 36271897
[TBL] [Abstract][Full Text] [Related]
36. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
[TBL] [Abstract][Full Text] [Related]
37. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.
De Waele L; Sakai K; Mancini I; Sinkovits G; Falter T; Inoue T; Agosti P; Rossmann H; Von Auer C; Tersteeg C; De Meyer SF; Joly BS; Veyradier A; Coppo P; Fijnheer R; Peyvandi F; Prohászka Z; Lämmle B; Vanhoorelbeke K
J Thromb Haemost; 2024 Feb; 22(2):493-502. PubMed ID: 37866519
[TBL] [Abstract][Full Text] [Related]
38. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity.
Tellier E; Widemann A; Cauchois R; Faccini J; Lagarde M; Brun M; Robert P; Robert S; Bachelier R; Poullin P; Roose E; Vanhoorelbeke K; Coppo P; Dignat-George F; Kaplanski G
Haematologica; 2023 Apr; 108(4):1127-1140. PubMed ID: 36453103
[TBL] [Abstract][Full Text] [Related]
39. Refractory immune TTP following Pfizer-BioNTech COVID-19 vaccine successfully salvaged with caplacizumab.
Laverdure E; Sperlich C; Fox S
J Thromb Haemost; 2022 Jul; 20(7):1696-1698. PubMed ID: 35510743
[TBL] [Abstract][Full Text] [Related]
40. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
